Recent therapeutic trials regarding the management of acute heart failure (AHF) failed to demonstrate the efficacy of newer therapeutic modalities and agents. Low-versus high-dose and continuous administration of furosemide were shown not to matter. Ultrafiltration was not found to be more efficacious than sophisticated diuretic therapy including dose-adjusted intravenous furosemide and metolazone. Dopamine and nesiritide were not shown to be superior to current therapy. Tezosentan and tovalptan had no effect on mortality. The development of rolofylline was terminated due to adverse effect (seizures). Lastly, preliminary experience with serelaxin indicates a mortality improvement at six months that remains to be confirmed. The disappointing findings of these recent trials may reflect the lack of efficacy of newer therapeutic modalities and agents. Alternatively the disappointing findings of these recent trials may be in part due to methodological issues. The AHF syndrome is complex with many clinical phenotypes. Failure to match clinical phenotypes and therapeutic modalities is likely to be partly responsible for the disappointing findings of recent AHF trials.
Introduction
Acute heart failure (AHF) is a heterogeneous and complex syndrome that associates central and/or peripheral fluid accumulation to a variable degree of end organ hypoperfusion. 1, 2 In contrast to the treatment of chronic heart failure (CHF), the treatment of AHF has not progressed over the past few decades. 3, 4 The syndrome of AHF heralds a poor prognosis and a high likelihood of recurrence requiring rehospitalisations. 5 In most instances AHF is related to progressive deterioration of CHF. Accordingly, hospitalisation for AHF should be viewed as an opportunity to optimise the medical regimen (adjustment of loop diuretic therapy, initiation of aldosterone receptor antagonism, titration of angiotensin-converting enzyme inhibition and beta-adrenergic blockade), and to consider cardiac resynchronisation therapy or referral for cardiac transplantation or mechanical circulatory support. 6 The syndrome of AHF comprises activation of multiple systems/pathways (neuro-hormonal, immune, inflammatory) in multiple organs (heart, kidney, liver, gastrointestinal tract and endothelium) that make management complex, and result in an unfavourable long-term outcome. 1, 7, 8 The use of Forrester classification, electrocardiogram (EKG) findings, laboratory data and bedside Doppler echocardiography allows for an individualised and tailored therapeutic management in a majority of AHF patient. 9, 10 However, tailored therapy based on right heart catheterisation findings has not been shown to translate into clinical benefits in randomised trials. Right heart catheterisation may be preferentially performed in patients who fail to improve with standard intravenous loop diuretic and vasodilator therapy. 11, 12 When AHF results from ongoing documented myocardial ischaemia, the treatment needs to be primarily targeted at relief of ischaemia. Systolic blood pressure (SBP) has been shown to have a large impact on AHF outcomes. Mortality rate at 2-3 months is 5% in patients when SBP is greater than 160 mm Hg on admission, 7% when SBP is between 120-160 mm Hg and 14% when SBP is lower than 120 mm Hg. 13 In addition to blood pressure, the treatment of AHF is adjusted for patient age, heart failure (HF) aetiology, severity and nature of left ventricular (LV) and right ventricular (RV) dysfunction and comorbid conditions (diabetes, chronic renal failure, anaemia, obesity, chronic obstructive pulmonary disease and peripheral vascular disease). Initial management aims at relieving pulmonary congestion and shortness of breath while assessing patients for end organ hypo-perfusion and causes of acute decompensation (arrhythmias, pulmonary or urinary infections, non-adherence to medical regimen). In the absence of hypotension, first-line therapy consists of loop diuretics and vasodilators. Alternative strategies for fluid removal, like nesiritide, endothelin, vasopressin or adenosine antagonists and veno-venous ultrafiltration, have been disappointing overall. [14] [15] [16] [17] After a brief overview of essential therapeutic targets in AHF, the present review will focus on recent randomised trials of loop diuretic therapy in AHF and newer interventions for fluid removal and cardiac unloading (see Appendix 1 for details of trials).
Therapeutic targets in AHF
The pathophysiology of AHF has been extensively reviewed. 4 Besides fluid overload, increased vascular stiffness and resistance play a key role in the pathophysiology of AHF. 1, 7, 18 Activation of vaso-constrictive pathways (sympathetic nervous system, angiotensin, endothelin and vasopressin) increases pulmonary and peripheral vascular resistances, aortic impedance and thereby lowers ventricular performance and results in 'afterload mismatch'. 7, 18, 19 The resulting steep increase in left ventricular (LV) filling pressure and alveolo-capillary barrier damage 20 contributes to pulmonary capillary fluid extravasation and pulmonary congestion and thereby hypoxia. Of note, low albumin level may also play a role in alveolar leakage. 21 Activation of vasoconstrictive pathways shunts venous blood to the heart, thus increasing right atrial pressure (RAP) and RV preload. Increased RAP also reduces the pressure gradient across the renal vasculature (mean BP minus RAP) and thereby renal filtration. 22 Risk factors for worsening renal function (acute kidney injury) include a background of hypertension and diabetes, a low-pressure gradient across the renal vasculature and the presence of incipient renal disease. 23, 24 Furthermore acute kidney injury and the development of loop diuretic resistance impede fluid removal in AHF. 25 Patients with AHF usually but not always present with elevated systemic vascular resistances. Patients with large acute myocardial infarction or advanced heart failure may occasionally present in AHF with a systemic inflammatory syndrome that markedly lowers systemic vascular resistances and requires the use of vasopressor agents to maintain a mean BP≥65 mm Hg. 8, 26 Fluid accumulates over a period of 1-2 weeks, with steady weight gain that precedes symptomatic deterioration in the majority of AHF patients. 27 Alternatively, patients may experience acute symptomatic deterioration without weight gain when heightened sympathetic activation mobilises the venous reservoir into the circulation where the increased effective circulatory volume begets pulmonary congestion. 3, 7, 18 Contributing factors to fluid accumulation such as excessive sodium intake, use of non-steroidal agents and acute kidney injury need to be addressed.
Diuretics

Loop diuretics
The aim of diuretic therapy is steady and progressive fluid removal without deterioration of renal function. Metaanalysis of small and relatively heterogeneous studies suggested that continuous administration of loop diuretics results in a more abundant diuresis and has a greater safety profile than bolus administration of loop diuretics. 28 However, the Diuretic Optimization Strategies Evaluation (DOSE) trial found no significant difference in efficacy or safety between both approaches in 308 AHF patients. 29 The high dose strategy (773 mg/72 h) when compared to the low-dose strategy (358 mg/72 h) was associated with a larger diuresis and favourable effects on secondary endpoints at the expense of a transient renal function worsening. The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial showed similar clinical efficacy of (a) high-dose furosemide (20 mg/h for 8 h), (b) low-dose furosemide (5 mg/h for 8 h), and (c) low-dose furosemide combined with low-dose dopamine (5 μg/kg/min) in 161 randomised patients hospitalised for acute decompensated heart failure (ADHF). 30 The ubiquitous role of loop diuretics in AHF management and the scarcity of relevant data mandate further investigation of their immediate and longterm effects.
Adjunct therapy with thiazide diuretics and aldosterone receptor antagonists
Combination diuretic therapy is often attempted in patients who have failed to respond to loop diuretics despite adequate systemic arterial pressure. Thiazide-type diuretics act on the distal convoluted tubule. When given in combination with a loop diuretic thiazide type diuretics have been reported to enhance diuresis and natriuresis. 31 Spironolactone, an aldosterone receptor antagonist, is often prescribed in combination with loop diuretics with the goal of alleviating potassium depletion. However, the combination of loop diuretics with thiazide type diuretics or aldosterone receptor antagonists has not been evaluated in placebo-controlled therapeutic trials. 32 
Ultra filtration
Veno-venous ultrafiltration (UF) is an emerging alternative approach to loop diuretic therapy for fluid removal in AHF. It presumably has the following advantages over loop diuretic therapy: (a) precise rate of fluid removal, (b) greater sodium loss and (c) lesser neuro-hormonal activation. 33, 34 The pilot Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial compared UF to standard care (furosemide 160 mg) in 40 patients with ADHF. Although fluid removal was greater in the UF arm, weight loss was similar at 24 h in patients who underwent UF and in those who received standard care. Patients who were assigned to UF had also received 80 mg of furosemide. 33 The Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure (UNLOAD) trial enrolled 200 patients with ADHF. 34 The UNLOAD trial showed that UF alone improved weight loss at 48 h (5.0 vs 3.1 kg, p<0.001), decreased the need for vasoactive drugs (3% vs 13%, p=0.02), and reduced the rate of hospital rehospitalisations at 90 days (18% vs 32%, p=0.02) compared to diuretic therapy with 181 mg of furosemide over 48 h. 34 In contrast the CARRESS study (Effectiveness of Ultrafiltration in Treating People with Acute Decompensated Heart Failure and Cardiorenal Syndrome), a NIHBLI sponsored trial, randomised 188 patients with ADHF and type 1 cardio-renal syndrome. The use of a stepped pharmacologic-therapy algorithm was superior to UF (without diuretic) for the preservation of renal function at 96 h, with a similar weight loss and a lower rate of adverse events than UF. 14 The risks associated with venous access and systemic anticoagulation are UF-related issues that need to be explored in larger patient cohorts. The Aquapheresis versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF) trial, which is enrolling 810 patients in 40 sites in the USA, is testing whether UF, as compared with intravenous diuretics before worsening renal function, reduces hospitalisations for ADHF. 35 At present, UF may be considered when loop diuretic therapy fails to resolve fluid accumulation (level of evidence C). 36 
Vasodilating agents
Low dose dopamine (2 μg/kg/min) produces intra-renal arterial vasodilation mediated by dopaminergic D1 receptors stimulation. The use of dopamine at low dose has been advocated to enhance diuresis. In the small Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial lowdose furosemide combined to low-dose dopamine was as effective as high-dose furosemide and associated with a lower rate of worsening renal function. 30 The larger DAD-HF II trial failed to find any benefit of adding dopamine to furosemide. 37 In the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial, lowdose dopamine did not enhance diuresis or improve renal function when added to diuretic therapy in patients with AHF and renal dysfunction. 38 In the absence of evidenced based data, intravenous administration of low dose dopamine may be viewed as a last attempt at pharmacological fluid removal before veno-venous UF in patients who fail to respond to loop diuretic therapy. 10 Nitrates are nitric oxide donors that produce venodilation at very low doses, thereby reducing cardiac preload and relieving pulmonary congestion. At higher doses nitrates dilate arteriolar vessels, lower systemic vascular resistance, reduce mitral/aortic regurgitation and improve forward stroke volume in patients with severe LV systolic dysfunction. 10, 39 Nitrates increased sublingual microvascular perfusion in patients with AHF. 40 In a randomised trial, intravenous boluses of high dose isosorbide dinitrate and low dose furosemide were more effective at 12 h than intravenous boluses of high dose furosemide and low dose isosorbide dinitrate in 104 patients with acute pulmonary oedema. 41 Attenuation of haemodynamic benefits have been reported with prolonged administration of nitroglycerin. However, concomitant administration of hydralazine may prevent tachyphylaxis to nitroglycerin. 42, 43 Patients with AHF and minimal or no weight change are the most suitable candidates (reduced venous capacitance and heightened arterial elastance) for combined therapy with low dose furosemide and high dose nitrates. Overall metaanalyses of reports regarding nitrates therapy for AHF did not reveal an increased rate of adverse events. 44 Compared to nesiritide, nitroglycerin exerts similar haemodynamic effects and reductions in plasma levels of brain natriuretic peptide (BNP) without affecting renal function. 45 Owing to a tolerance phenomenon, up-titration of nitrates is needed over time and increased production of reactive oxygen species (ROS) may be of concern with prolonged nitrates administration. 46 Given these issues prolonged monotherapy with nitrates is not recommended. Short-term therapy with nitrates may be of use in the management of AHF as it lessens the need for loop diuretic therapy. 10 Nitroprusside a potent arterial and venous vasodilator is useful in patients with AHF and severe hypertension. When carefully titrated and closely monitored, nitroprusside seldom produces thiocyanate toxicity. 47, 48 Due to the risk of 'coronary steal' nitroprusside may be detrimental in patients with recent myocardial infarction. 49 Safe nitropusside administration requires invasive monitoring of arterial pressure and serial thiocyanate level determinations.
Morphine is an adjunctive therapy in AHF. Morphine produces venodilation and anxiety relief. However it should be avoided in patients with unclear diagnosis, impaired mental status or respiratory drive.
Nesiritide is a recombinant BNPBNP. Nesiritide produces dose-dependent reductions in filling pressure, systemic and pulmonary vascular resistance, while increasing cardiac output in patients with LV systolic dysfunction. Promising results were initially observed in the efficacy trial of the Nesiritide Study Group. 50 Compared to placebo and low dose nitroglycerin in the Vasodilatation in the Management of Acute CHF (VMAC) trial nesiritide was associated with a greater decrease in pulmonary capillary wedge pressure at 3 and 24 h. 51 When compared to placebo, nesiritide improved dyspnoea at 3 h. However, meta-analyses of randomised trials suggested that nesiritide, was associated with a greater rate of worsening renal function and early death than placebo. The recent large placebo controlled Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial showed that nesiritide does not improve dyspnoea and does not affect mortality and morbidity as evidenced by unchanged rate of HF re-hospitalisations and renal function. 52 The ROSE-AHF trial evaluated the efficacy low dose nesiritide in patients with AHF and kidney dysfunction (estimated glomerular filtration rate (eGFR) 15-60 ml/ min/m²). 38 Low-dose nesiritide did not enhance fluid removal or improve renal function when added to loop diuretic therapy. Accordingly, nesiritide is no longer used in the treatment of HF.
Relaxin-2 is a naturally secreted peptide hormone during pregnancy. Relaxin-2 dilates systemic and renal vascular beds, and has anti-inflammatory, anti-fibrotic and pro-angiogenic effects. Relaxin exerts its effects through cyclic AMP and nitric oxide stimulation and activation of the endothelin type B receptor. 53 Serelaxin, a recombinant form of human relaxin-2, yielded promising haemodynamic and neurohormonal effects in phase II studies. In the larger placebo controlled serelaxin, recombinant human relaxin-2, for treatment of Acute Heart Failure (RELAX-AHF) trial, a 48 h infusion of serelaxin (30 μg/kg/d) improved dyspnoea and resulted in lower 180-day mortality in AHF patients with a SBP greater than 125 mm Hg who were not receiving nitrates or nitroprusside therapy. 54 The adequately powered RELAX-AHF2 randomised trial is now assessing the mortality benefit of serelaxin against placebo. Cardiovascular mortality during at 180 days is the primary endpoint of RELAX-AHF2. Serelaxin has not yet been approved for AHF in the US and Europe.
Tezosentan, a non-selective antagonist of the endothelin-1 receptor, was found to reduce LV filling pressure, systemic vascular resistances and plasma BNP levels in the Randomized Intravenous TeZosentan (RITZ) trials. 55 However the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) was prematurely terminated because of a low probability of achieving a significant treatment effect. Compared to placebo, intravenous administration of tesozentan (5 mg/h for 30 min, followed by 1 mg/h for 24-72 h) did not improve dyspnoea or survival, and did not affect the rate of worsening heart failure at seven days. 56 Tezosentan is not currently used for AHF.
Tolvaptan and conivaptan are arginine vasopressin receptor antagonists that block V2 and V1a/V2 receptors respectively in the collecting ducts of the nephron. Tovalptan and conivaptan promote the loss of electrolyte free water or aquapheresis. 57 Tolvaptan and conivaptan deter the systemic effects of arginine vasopressin in HF that are directly related to HF severity and contribute to vasoconstriction, hyponatraemia, aldosterone release and ventricular remodelling. 58 Short-term treatment with arginine vasopressin receptor antagonists including tolvaptan and conivaptan improved fluid management and haemodynamics. 59 Fluid excretion achieved with these agents has been associated with improved renal function and electrolyte balance compared with loop diuretic administration. With tolvaptan, the efficacy of selective vasopressin V2 receptor antagonism was evaluated in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan (EVEREST) trial. 16 Tolvaptan did not alter long term outcome (all-cause mortality, cardiovascular mortality or subsequent HF hospitalisations) despite favourable effects on body weight and serum sodium. 16, 57 Conivaptan, which combines V1a/V2 receptor antagonism, reduces cardiac loading conditions. The long-term effects of conivaptan have not been studied. 60 Rolofylline is an adenosine A1−receptor antagonist. It blocks A1-adenosine receptors in the renal afferent arterioles. Increased intra-renal adenosine concentration has been associated with worsening renal function and diuretic resistance. Hydrolysis of ATP releases free adenosine into the extracellular space. The resulting activation of adenosine A1 receptors lowers renal blood flow and glomerular filtration rate (GFR) thereby stimulating release of renal renin. In addition, A1-receptor activation enhances proximal tubular sodium reabsorption. In patients with CHF, A1-receptor antagonists may enhance sodium excretion, and improve diuretic responsiveness while preserving GFR. 61, 62 Efficacy of rolofylline in patients with AHF and impaired renal function (eGFR ranging from 20-80 ml per min using Cockcroft−Gault equation), was evaluated in the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial. 15 Daily intravenous rolofylline (30 mg) for up to three days compared to placebo did not improve symptoms, survival or HF hospitalisations. The rolofylline development program has been terminated.
Ularitide is the synthetic version of urodilatin, the renal natriuretic peptide (NP) which is released by renal tubular cells and regulates renal sodium and water excretion. Through guanylate cyclase activation ularitide is associated with pre-glomerular vasodilation and post-glomerular vasoconstriction, thereby increasing GFR. In the phase II Safety and Efficacy of an Intravenous Placebo-Controlled Randomized Infusion of Ularitide in a Prospective Doubleblind Study (SIRIUS) trial, ularitide at 15 ng/kg/min lowered serum blood urea nitrogen (BUN), increased cardiac output, and preserved the mean BP-RAP pressure gradient; thereby enhancing renal perfusion. 63 Phase III URGENT (n>3000) and Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure (TRUE-AHF) (n=2116) trials are ongoing. Specifically TRUE-AHF is a randomised double blind placebo-controlled trial with two co-primary efficacy endpoints including cardiovascular mortality for the entire duration of the trial and a composite one at short term (48 h).
Other vasodilators that activate soluble guanylate cyclase like a chimeric natriuretic peptide C-D and cinaciguat exerting potent venous and arterial vasodilation are currently being evaluated. 64, 65 
Negative trials and methodological issues
Overall none of the recent trials of new therapeutic modalities have shown a definite improvement over existing therapies. Thus at the present time none of the agents under investigation appears to have a clear advantage over current therapy. Such negative results may truly reflect the lack of novel efficacious agents for the pharmacological treatment of AHF. Alternatively the failure to demonstrate the efficacy of novel agents may reflect methodological issues. As above mentioned, AHF is a complex and heterogeneous condition with a multitude of pathological processes, underlying mechanisms, patient phenotypes, de novo versus recurrent AHF and end-organ malfunctions. The likelihood of observing a statistical difference between two interventions is hindered by the complexity and heterogeneity of AHF as a given intervention may not benefit the whole AHF population. Therapies that aim at fluid removal and/or cardiac unloading can only benefit patients who have no systemic hypotension with clear evidence of fluid accumulation. Any attempt at fluid removal or cardiac unloading is likely to be detrimental in patients with hypotension, low cardiac output and minimal fluid accumulation. Thus better identification of the AHF phenotype that may respond to a given intervention is essential to ensure therapeutic success. At the present time novel therapies for AHF are investigated without concerns for AHF phenotypes.
More importantly, in none of the above mentioned therapeutic trials was an effort was made to elucidate the cascade of events that led to the acute presentation. It is well accepted that resuming medications consistently results in symptomatic improvement in patients who, non-adherent to medications, are hospitalised for AHF. Assuming that such patients represented a substantial proportion of the therapeutic trial population, this in fact decreased the trial population by half as such patients were likely to respond equally well to the strategies under investigation. In other terms, sample size calculation is blemished by the proportion of patients who due to the nature of the intervention at hand are unlikely to experience a beneficial response to the intervention. The negative results of these rigorously conducted but inadequately designed trials of fluid removal and vasodilation in AHF were not entirely unexpected. 38 (2013) Addition of placebo or lowdose dopamine ( 
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